Compare Stocks: LYEL, ODTX, OMER, and MGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LYEL Lyell Immunopharma	$12.88 -4.8%	$14.12	$11.47 ▼ $45.00	$331.54M	-0.04	102,689 shs	101,565 shs
MGTX MeiraGTx	$13.26 -2.0%	$13.25	$6.62 ▼ $15.35	$1.30B	1.27	715,216 shs	534,365 shs
ODTX Odyssey Therapeutics	$24.51 -9.1%	$20.98	$15.10 ▼ $29.05	$1.30B	N/A	162,006 shs	217,404 shs
OMER Omeros	$19.39 +1.4%	$14.09	$3.94 ▼ $19.65	$1.38B	2.6	2.33 million shs	1.49 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LYEL Lyell Immunopharma	-4.80%	-13.85%	-10.12%	-6.12%	-2.05%
MGTX MeiraGTx	-2.00%	-5.69%	+1.84%	+38.13%	+73.33%
ODTX Odyssey Therapeutics	-9.12%	-7.93%	+10.55%	+45.81%	+2,450,999,900.00%
OMER Omeros	+1.41%	+2.81%	+42.36%	+90.47%	+355.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LYEL Lyell Immunopharma	$12.88 -4.8%	$14.12	$11.47 ▼ $45.00	$331.54M	-0.04	102,689 shs	101,565 shs
MGTX MeiraGTx	$13.26 -2.0%	$13.25	$6.62 ▼ $15.35	$1.30B	1.27	715,216 shs	534,365 shs
ODTX Odyssey Therapeutics	$24.51 -9.1%	$20.98	$15.10 ▼ $29.05	$1.30B	N/A	162,006 shs	217,404 shs
OMER Omeros	$19.39 +1.4%	$14.09	$3.94 ▼ $19.65	$1.38B	2.6	2.33 million shs	1.49 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LYEL Lyell Immunopharma	-4.80%	-13.85%	-10.12%	-6.12%	-2.05%
MGTX MeiraGTx	-2.00%	-5.69%	+1.84%	+38.13%	+73.33%
ODTX Odyssey Therapeutics	-9.12%	-7.93%	+10.55%	+45.81%	+2,450,999,900.00%
OMER Omeros	+1.41%	+2.81%	+42.36%	+90.47%	+355.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LYEL Lyell Immunopharma	2.78	Moderate Buy	$40.86	217.21% Upside
MGTX MeiraGTx	3.00	Buy	$26.17	97.34% Upside
ODTX Odyssey Therapeutics	2.63	Moderate Buy	$35.75	45.86% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	95.98% Upside

Current Analyst Ratings Breakdown

Latest LYEL, ODTX, OMER, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/27/2026	ODTX Odyssey Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
8/27/2026	ODTX Odyssey Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
8/14/2026	LYEL Lyell Immunopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/14/2026	LYEL Lyell Immunopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/14/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $27.00
8/13/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/11/2026	ODTX Odyssey Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/7/2026	ODTX Odyssey Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$26.00 ➝ $29.00
8/6/2026	LYEL Lyell Immunopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
8/5/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LYEL Lyell Immunopharma	$40K	7,889.00	N/A	N/A	$11.68 per share	1.10
MGTX MeiraGTx	$81.39M	15.65	N/A	N/A	($0.07) per share	-189.43
ODTX Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	$1.90 per share	10.22	($1.71) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LYEL Lyell Immunopharma	-$274.45M	-$12.83	N/A	N/A	N/A	-920,285.25%	-91.62%	-70.50%	11/10/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	18.68	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)
ODTX Odyssey Therapeutics	N/A	-$6.77	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OMER Omeros	-$3.35M	$1.28	15.15	17.16	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)

Latest LYEL, ODTX, OMER, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/6/2026	Q2 2026	LYEL Lyell Immunopharma	-$1.94	-$1.9180	+$0.0220	-$1.92	$0.00 million	$0.00 million
8/5/2026	Q2 2026	ODTX Odyssey Therapeutics	N/A	-$1.74	N/A	-$1.74	N/A	N/A
6/17/2026	Q1 2026	ODTX Odyssey Therapeutics	-$1.31	-$6.77	-$5.46	-$6.77	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
ODTX Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LYEL Lyell Immunopharma	N/A	5.36	5.36
MGTX MeiraGTx	0.46	3.76	3.76
ODTX Odyssey Therapeutics	N/A	11.36	11.36
OMER Omeros	N/A	1.95	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LYEL Lyell Immunopharma	66.05%
MGTX MeiraGTx	67.48%
ODTX Odyssey Therapeutics	N/A
OMER Omeros	48.79%

Insider Ownership

Company	Insider Ownership
LYEL Lyell Immunopharma	6.20%
MGTX MeiraGTx	7.40%
ODTX Odyssey Therapeutics	N/A
OMER Omeros	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LYEL Lyell Immunopharma	270	24.50 million	22.99 million	Optionable
MGTX MeiraGTx	300	96.04 million	88.94 million	Optionable
ODTX Odyssey Therapeutics	N/A	48.06 million	N/A	N/A
OMER Omeros	210	72.39 million	64.79 million	Optionable

LYEL, ODTX, OMER, and MGTX Headlines

Recent News About These Companies

Bank of New York Mellon Corp Makes New Investment in Omeros Corporation $OMER

September 9 at 3:28 AM | marketbeat.com

Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 9 at 2:14 AM | americanbankingnews.com

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Analysts

September 9 at 2:13 AM | marketbeat.com

Ancora Advisors LLC Boosts Stock Holdings in Omeros Corporation $OMER

September 3, 2026 | marketbeat.com

Bank of America Corp DE Raises Stock Holdings in Omeros Corporation $OMER

September 2, 2026 | marketbeat.com

Top Omeros Executive Makes Eye-Catching Move With Insider Stock Sale

September 1, 2026 | tipranks.com

Peter Cancelmo Sells 25,000 Shares of Omeros (NASDAQ:OMER) Stock

September 1, 2026 | marketbeat.com

BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER

September 1, 2026 | marketbeat.com

75,053 Shares in Omeros Corporation $OMER Bought by Deutsche Bank AG

September 1, 2026 | marketbeat.com

659,730 Shares in Omeros Corporation $OMER Bought by Corient Private Wealth LP

August 31, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) Director Arnold Hanish Sells 5,000 Shares of Stock

August 29, 2026 | insidertrades.com

Arnold Hanish Sells 5,000 Shares of Omeros (NASDAQ:OMER) Stock

August 28, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) Director Arnold Hanish Sells 10,000 Shares

August 28, 2026 | marketbeat.com

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

August 28, 2026 | zacks.com

Ancora Advisors LLC Purchases New Stake in Omeros Corporation $OMER

August 28, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) CAO Sells 906 Shares of Stock

August 26, 2026 | insidertrades.com

David Borges Sells 906 Shares of Omeros (NASDAQ:OMER) Stock

August 25, 2026 | marketbeat.com

David Borges Sells 10,000 Shares of Omeros (NASDAQ:OMER) Stock

August 25, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) Hits New 52-Week High - Should You Buy?

August 25, 2026 | marketbeat.com

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

August 25, 2026 | zacks.com

Omeros Corporation (OMER) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LYEL, ODTX, OMER, and MGTX Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

$12.88 -0.65 (-4.80%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$12.99 +0.11 (+0.85%)

As of 07:59 AM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

MeiraGTx NASDAQ:MGTX

$13.26 -0.27 (-2.00%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$13.29 +0.03 (+0.23%)

As of 09:15 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Odyssey Therapeutics NASDAQ:ODTX

$24.51 -2.46 (-9.12%)

As of 09/9/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Omeros NASDAQ:OMER

$19.39 +0.27 (+1.41%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$19.24 -0.15 (-0.75%)

As of 09:04 AM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, ODTX, OMER, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, ODTX, OMER, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, ODTX, OMER, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LYEL, ODTX, OMER, and MGTX Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

MeiraGTx NASDAQ:MGTX

Odyssey Therapeutics NASDAQ:ODTX

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, ODTX, OMER, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, ODTX, OMER, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, ODTX, OMER, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LYEL, ODTX, OMER, and MGTX Company Descriptions

Lyell Immunopharma NASDAQ:LYEL

MeiraGTx NASDAQ:MGTX

Odyssey Therapeutics NASDAQ:ODTX

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools